Propanc Biopharma, Inc.

PPCB Nasdaq SEC CIK 1517681
Follow Propanc Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2027 USD · US GAAP
Net income −$8.6M −77.5% vs same quarter last year
EPS, diluted −$12.22
Operating cash flow −$2M −1.6% vs same quarter last year
Operating income −$8.6M −83.4% vs same quarter last year
Net income by quarter
−$430.2K
−$54.1M
−$4.1M
−$4.8M
−$3.1M
−$6.4M
−$4.6M
−$8.6M
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearNet income
FY26−$18.9M
FY25−$58.9M
FY24−$1.8M
FY23−$2.7M
FY22−$2.7M
FY21−$2M
FY20−$4.7M
FY19−$5.8M
FY18−$7M
FY17−$7.9M
FY16−$9.4M
FY15−$3.4M
FY14−$829.6K
FY13−$1.4M
FY12−$11.4M
Free cash flowOperating cash flow minus capital expenditure
−$6M−$4M−$2M$0$2MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$5.7M
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$2.1M
FY18-
FY17-
FY16−$4.5M
FY15−$1.4M
FY14$226.4K
FY13-
FY12-